Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
--------
Question: All 46 schools in the district serving Grand Junction and the surrounding area were closed and won't reopen until after the Thanksgiving break so custodians can disinfect surfaces. Norovirus is a highly contagious bug that causes diarrhea, vomiting and other symptoms, and can spread quickly in public places. It's most common in winter but can be seen any time of year. The outbreak was first seen last week at a high school before spreading to other schools. Officials in the district, the largest in western Colorado with 22,000 students, believe there is now another related strain of the virus that has affected some students who were previously sick. "We are taking this highly unusual action because this virus is extremely contagious and spreading quickly across our schools," district nursing coordinator Tanya Martin said. It's not clear how many students have become sick. Some custodians also became ill, slowing down the cleaning process, but it's unknown if the suspected viruses were to blame. Nicole Comstock, communicable disease deputy branch chief for the state Department of Public Health and Environment, told The Daily Sentinel that there are about 150 to 200 suspected norovirus outbreaks in the state each year. She said most occur at nursing homes but outbreaks at schools are not uncommon. The U.S. Air Force Academy outside Colorado Springs reported that 400 cadets have been sickened by norovirus since October, but the outbreak hasn't disrupted classes. The Gazette reported that infected cadets are kept on bed rest for at least three days after their symptoms disappear before they can be cleared to return to class and training.

Answer: Suspected norovirus outbreak closes 46 Colorado schools.

Question: As he did following last month's Las Vegas massacre of 58 people, Trump resisted any discussion of gun control during a news conference in Tokyo, where he was beginning his first presidential trip to Asia. Instead, Trump characterized the shooting as a "mental health problem at the highest level." Yet White House officials said Trump is unlikely to call for a specific policy response, as he did after last week's Islamic State group-inspired truck attack, which killed eight people in New York City. Devin Kelley, the Texas gunman, was discharged from the Air Force several years ago for assaulting his spouse and a child, the Air Force said. "This was a very based on preliminary reports a very deranged individual. A lot of problems over a long period of time," Trump said when asked about the shooting as he and Japanese Prime Minister Shinzo Abe held a joint news conference. Trump's more muted response to gun violence contrasts with his swift call for legislative and military action following the Oct. 31 truck attack in New York City. Within hours of a rental truck ramming through a crowded bicycle path and into a school bus, Trump called for Congress to "immediately" repeal the diversity visa lottery program that suspect Sayfullo Saipov, an Uzbekistan citizen, used to enter the country in 2010. Trump also claimed that the U.S. had already stepped up its retaliation against the Islamic State group after the attack. "We are hitting them 10 times harder," he said Friday. After the Las Vegas shooting, Trump and aides said it was inappropriate to consider a policy response while people were still grieving. Despite days later suggesting openness to outlawing the bump stock device that allowed Las Vegas shooter Stephen Paddock to fire at near-automatic rates, the Trump administration has shown no signs of urgency. "He has asked that that process be reviewed, and we're waiting on some of the details of that to take place," White House Press Secretary Sarah Sanders said Oct. 27 when asked about bump stocks. "But a decision hasn't been finalized on that. " Trump, who supported gun control before reversing his position to enter the Republican presidential primary, courted the National Rifle Association's endorsement in 2016, and earlier this year became the first president in three decades to speak at the gun group's annual convention. In February, Trump signed legislation reversing an Obama-era regulation that would have made it harder for Americans with mental illnesses to buy a gun. Under the Obama rule, the Social Security Administration would have been required to send in the names of beneficiaries with mental impairments who needed a third party to manage their financial affairs. The rule would have affected an estimated 75,000 beneficiaries who would have been added to the national background check database. The attack happened in South Texas on Sunday morning when a man dressed in black tactical-style gear and armed with an assault rifle opened fire inside a Baptist church in a small community, killing 26 people and wounding 20 others in the deadliest mass shooting in state history. As Kelley left the scene, authorities said, he was confronted by an armed resident. Kelley later was found dead in his vehicle. Trump said, "Fortunately somebody else had a gun that was shooting in the opposite direction, otherwise it (wouldn't) have been as bad as it was. It would have been much worse." Investigators believe Kelley shot himself. ___ Associated Press writers Kevin Freking, Catherine Lucey and Darlene Superville in Washington contributed to this report.

Answer: Trump: Texas mass shooting is about mental health, not guns.

Question: That's the premise behind the recent approval of a landmark drug, the first cancer therapy ever cleared based on a tumor's genetics instead of the body part it struck first. Now thousands of patients with worsening cancer despite standard treatment can try this immunotherapy as long as genetic testing of the tumor shows they're a candidate. "It's like having a lottery ticket," said Johns Hopkins oncologist Dr. Dung Le, who helped prove the new use for the immunotherapy Keytruda. "We've got to figure out how to find these patients, because it's such a great opportunity for them." Today, doctors diagnose tumors by where they originate breast cancer in the breast, colon cancer in the colon and use therapies specifically tested for that organ. In contrast, the Food and Drug Administration labeled Keytruda the first "tissue-agnostic" treatment, for adults and children. The reason: Seemingly unrelated cancers occasionally carry a common genetic flaw called a mismatch repair defect. Despite small studies, FDA found the evidence convincing that for a subset of patients, that flaw can make solid tumors susceptible to immunotherapy doctors otherwise wouldn't have tried. "We thought these would be the hardest tumors to treat. But it's like an Achilles heel," said Hopkins cancer geneticist Bert Vogelstein. And last month FDA Commissioner Scott Gottlieb told a Senate subcommittee his agency will simplify drug development for diseases that "all have a similar genetic fingerprint even if they have a slightly different clinical expression." It's too early to know if what's being dubbed precision immunotherapy will have lasting benefits, but here's a look at the science. WHO'S A CANDIDATE? Hopkins estimates about 4 percent of cancers are mismatch repair-deficient, potentially adding up to 60,000 patients a year. Widely available tests that cost $300 to $600 can tell who's eligible. The FDA said the flaw is more common in colon, endometrial and gastrointestinal cancers but occasionally occurs in a list of others. "Say, 'have I been tested for this?'" is Le's advice for patients. MUTATIONS AND MORE MUTATIONS Most tumors bear 50 or so mutations in various genes, Vogelstein said. Melanomas and lung cancers, spurred by sunlight and tobacco smoke, may have twice as many. But tumors with a mismatch repair defect can harbor 1,500 mutations. Why? When DNA copies itself, sometimes the strands pair up wrong to leave a typo a mismatch. Normally the body spell checks and repairs those typos. Without that proofreading, mutations build up, not necessarily the kind that trigger cancer but bystanders in a growing tumor. THE PLOT THICKENS Your immune system could be a potent cancer fighter except that too often, tumors shield themselves. Merck's Keytruda and other so-called checkpoint inhibitors can block one of those shields, allowing immune cells to recognize a tumor as a foreign invader and attack. Until now, those immunotherapies were approved only for a few select cancers Keytruda hit the market for melanoma in 2014 and they work incredibly well for some patients but fail in many others. Learning who's a good candidate is critical for drugs that can cost $150,000 a year and sometimes cause serious side effects. In 2012, Hopkins doctors testing various immunotherapies found the approach failed in all but one of 20 colon cancer patients. When perplexed oncologists told Vogelstein, "a light bulb went off." Sure enough, the one patient who fared well had a mismatch repair defect and a "mind-boggling" number of tumor mutations. The more mutations, the greater the chance that at least one produces a foreign-looking protein that is a beacon for immune cells, Vogelstein explained. It was time to see if other kinds of cancer might respond, too. WHAT'S THE DATA? The strongest study, published in the journal Science, tested 86 such patients with a dozen different cancers, including some who had entered hospice. Half had their tumors at least shrink significantly, and 18 saw their cancer become undetectable. It's not clear why the other half didn't respond. Researchers found a hint, in three patients, that new mutations might form that could resist treatment. But after two years of Keytruda infusions, 11 of the "complete responders" have stopped the drug and remain cancer-free for a median of eight months and counting. Catherine "Katie" Rosenbaum, 67, is one of those successes. The retired teacher had her uterus removed when endometrial cancer first struck, but five years later tumors returned, scattered through her pelvis and colon. She tried treatment after treatment until in 2014, her doctor urged the Hopkins study. Rosenbaum took a train from Richmond, Virginia, to Baltimore for infusions every two weeks and then, after some fatigue and diarrhea side effects, once a month. Then the side effects eased and her tumors started disappearing. A year into the study she was well enough to swim a mile for a Swim Across America cancer fundraiser. "Nothing else had worked, so I guess we could say it was a last hope," said Rosenbaum, who now wants other patients to know about the option. ___ This Associated Press series was produced in partnership with the Howard Hughes Medical Institute's Department of Science Education. The AP is solely responsible for all content.

Answer:
Tumor gene testing urged to tell if drug targets your cancer.